Author + information
- Kristi Reynolds,
- T. Craig Cheetham,
- Shen-Chih Chang,
- Jin-Wen Y. Hsu,
- Rong Wei,
- Deborah S. Ling-Grant,
- Teresa Harrison,
- Susan H. Boklage,
- Victoria Romo-LeTourneau and
- Ronald Scott
Background: The 2013 ACC/AHA Cholesterol Treatment Guideline identified 4 statin treatment benefit groups and provided recommendations on intensity of statin therapy. To understand the impact of the guideline, we examined trends in statin use among adults in an integrated health care delivery system from 2009-2015.
Methods: Adults aged ≥21 years were identified from electronic health records. Trends in statin use and appropriate statin intensity were analyzed by statin benefit group: history of atherosclerotic cardiovascular disease (ASCVD), LDL-C ≥190 mg/dL in the last year, diabetes (DM) (aged 40-75 years), or 10-year ASCVD risk ≥7.5% (aged 40-75 years).
Results: Roughly 2 million adults were included each year: 5.7% had ASCVD, 0.7% had LDL-C ≥190 mg/dL, 6.3% had DM and 10.6% had 10-year ASCVD risk ≥7.5%. Statin treatment rates were stable over time for adults with ASCVD (2009: 77.8%; 2015: 79.8%), LDL-C ≥190 mg/dL (2009: 44.6%; 2015: 43.7%) and DM (2009: 77.4%; 2015: 79.2%) but increased significantly for adults with 10-year ASCVD risk ≥7.5% (2009: 36.2%; 2015: 46.6%). The proportion of adults on high intensity statins increased substantially over time in all statin benefit groups (Figure). Use of recommended intensity statins increased 52% in those with ASCVD, 133% in LDL-C ≥190 mg/dL, 67% in DM and 49% in 10-year ASCVD risk ≥7.5%.
Conclusions: Statin use and use of high intensity statins in this health system trended up from 2009-2015, nonetheless, there is room for improvement to further reduce CV events.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Advances in Cholesterol Measurement and Management
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1106-040
- 2017 American College of Cardiology Foundation